Johnson & Johnson (JNJ) Net Margin Growth (3y) (2012 - 2026)

Johnson & Johnson (JNJ) Net Margin Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (3y) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 1,803.00
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 1,973.00
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 544.00
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 30,838.00
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4,534.00
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -2,543.00
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 1,355.00
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -58.00
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -323.00

Historic Data

Download Data
DateValue
Mar 29, 2026 1,973.00
Dec 28, 2025 1,936.00
Sep 28, 2025 2,073.00
Jun 29, 2025 2,059.00
Mar 30, 2025 4,733.00
Dec 31, 2023 -812.00
Oct 1, 2023 8,487.00
Jul 2, 2023 -2,085.00
Apr 2, 2023 -2,599.00
Jan 1, 2023 -1,786.00
Oct 2, 2022 -772.00
Jul 3, 2022 -2,454.00
Apr 3, 2022 -1,581.00
Oct 3, 2021 -362.00
Jul 4, 2021 795.00
Apr 4, 2021 594.00
Jan 3, 2021 6,078.00
Sep 27, 2020 -230.00
Jun 28, 2020 -54.00
Mar 29, 2020 312.00